Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.12
▼(-17.14% Downside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by weak financial performance—zero revenue in the latest year, persistent losses, and worsening cash burn—partly offset by a comparatively strong equity-backed balance sheet. Technicals are also soft with the price below key moving averages and negative MACD, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Equity-backed balance sheet
A sizable equity cushion relative to total assets materially reduces near-term insolvency risk and gives management flexibility to fund R&D, pursue partnerships, or absorb setbacks without immediate distress financing. This bolsters durability over the next several months.
Negative Factors
Revenue collapse
A complete loss of reported revenue is a structural red flag: it removes internal funding sources, weakens commercial validation, and forces greater reliance on external financing or partners. This materially raises execution and financing risk over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity-backed balance sheet
A sizable equity cushion relative to total assets materially reduces near-term insolvency risk and gives management flexibility to fund R&D, pursue partnerships, or absorb setbacks without immediate distress financing. This bolsters durability over the next several months.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.60M
Dividend YieldN/A
Average Volume (3M)525.22K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue GrowthN/A
EPS Growth21.23%
CountryAU
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics Limited is an Australian pharmaceutical company dedicated to pioneering focal adhesion kinase (FAK) inhibitors, with a focus on both oncology and chronic fibrotic diseases. A key asset in its development pipeline is AMP945, a F...
How the Company Makes Money
Amplia Therapeutics generates revenue primarily through partnerships, licensing agreements, and collaborations with large pharmaceutical firms and healthcare organizations. The company leverages its proprietary drug candidates and intellectual pro...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.78M | 4.45M | 1.19M | 1.98M |
| Gross Profit | -92.14K | 3.57M | 4.01M | 1.12M | 1.98M |
| EBITDA | -13.09M | -6.78M | -4.48M | -7.26M | -3.64M |
| Net Income | -7.71M | -6.57M | -4.50M | -6.24M | -3.64M |
Balance Sheet | |||||
| Total Assets | 41.44M | 22.94M | 14.85M | 18.68M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 10.86M | 3.39M | 9.26M | 14.61M |
| Total Debt | 341.11K | 13.89K | 1.59M | 2.27M | 2.10M |
| Total Liabilities | 1.97M | 1.91M | 3.43M | 2.85M | 2.64M |
| Stockholders Equity | 39.47M | 21.02M | 11.42M | 15.84M | 21.85M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -6.89M | -5.13M | -5.31M | -4.42M |
| Operating Cash Flow | -8.73M | -6.89M | -5.13M | -5.29M | -4.40M |
| Investing Cash Flow | -96.22K | -2.07K | -2.23K | -58.42K | -26.64K |
| Financing Cash Flow | 25.94M | 14.32M | -772.98K | -84.22K | 17.19M |
Amplia Therapeutics Technical Analysis
Negative
0.14
Price Trends
0.14
Negative
0.14
Negative
0.14
Negative
Market Momentum
>-0.01
Negative
46.13
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.14, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.13 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ATX.
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.68B | 55.17 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$52.22M | -8.10 | -104.56% | ― | ― | 57.89% | |
43 Neutral | AU$61.60M | -7.66 | -18.71% | ― | ― | 21.23% | |
43 Neutral | AU$105.59M | -2.06 | -265.55% | ― | -26.58% | -100.90% | |
39 Underperform | AU$127.24M | -8.16 | -30.19% | ― | ― | 62.66% | |
39 Underperform | AU$5.95M | -1.60 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.12
-0.08
-41.46%
AU:ENP
Tryptamine Therapeutics
0.03
<0.01
3.23%
AU:NEU
Neuren Pharmaceuticals Limited
13.25
0.71
5.66%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.12
-40.00%
AU:ATH
Alterity Therapeutics
0.59
0.03
6.36%
AU:ZLD
Zelira Therapeutics
0.50
0.05
11.11%
Amplia Therapeutics Corporate Events
Amplia lodges updated ASX corporate governance statement for 2026
May 29, 2026
Amplia Therapeutics has lodged its updated corporate governance statement for the year ended 31 March 2026, confirming that the document is current as of 27 May 2026 and is available on its website. The filing, accompanied by a completed Appendix ...
Amplia Therapeutics details ASX-aligned corporate governance framework
May 29, 2026
Amplia Therapeutics has formalised its governance framework in line with the ASX Corporate Governance Council’s latest principles, detailing a clear Board Charter that defines the respective roles of directors and management. The board retai...
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
May 29, 2026
Amplia Therapeutics has released its 2025-2026 annual report, underscoring its commitment to innovating therapies for cancer and fibrotic diseases. The report positions the company as a purpose-driven biotech player, highlighting its broader focus...
Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance
May 12, 2026
Amplia Therapeutics has issued 240,385 fully paid ordinary shares following the exercise of Zero Exercise Price Options granted to its Chief Medical Officer under the company’s Equity Incentive Plan. The new shares rank equally with existing...
Amplia Therapeutics Adds 240,385 New Shares to ASX Listing
May 12, 2026
Amplia Therapeutics Limited has applied for quotation of 240,385 new ordinary fully paid shares on the Australian Securities Exchange. The new securities, issued on May 12, 2026, arise from the exercise or conversion of existing options or other c...
Amplia and ANZGOG launch narmafotinib ovarian cancer trial targeting high‑need patients
May 8, 2026
Amplia Therapeutics has partnered with the Australia New Zealand Gynaecological Oncology Group to run a new investigator-initiated trial of its lead FAK inhibitor narmafotinib in ovarian cancer, expanding beyond its current pancreatic cancer progr...
Amplia advances narmafotinib program with strong pancreatic cancer data and Phase 3 readiness steps
Apr 28, 2026
Amplia Therapeutics reported further clinical and operational progress for its lead FAK inhibitor narmafotinib in the March 2026 quarter, highlighted by mature data from the ACCENT trial in metastatic pancreatic cancer showing a median overall sur...
Amplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
Apr 8, 2026
Amplia Therapeutics has paused further recruitment in its AMPLICITY clinical trial in advanced pancreatic cancer after three dose-limiting toxicities were linked to the chemotherapy regimen mFOLFIRINOX, while confirming no toxicity concerns relate...
Amplia Halts AMPLICITY Recruitment, Shifts Focus to Less Toxic Pancreatic Cancer Regimens
Apr 6, 2026
Amplia Therapeutics has halted further recruitment in its AMPLICITY trial in advanced pancreatic cancer, after three dose-limiting toxicities were linked to the chemotherapy regimen mFOLFIRINOX rather than to its lead drug narmafotinib. Eight pati...
Amplia posts unprecedented complete responses and survival gain in pancreatic cancer trial
Mar 22, 2026
Amplia Therapeutics reported mature data from its Phase 1b/2a ACCENT trial in advanced pancreatic cancer, showing that five patients achieved a complete response when treated with narmafotinib plus gemcitabine-Abraxane, an unprecedented 7.8% compl...
Amplia requests ASX trading halt ahead of key clinical trial data
Mar 19, 2026
Amplia Therapeutics has requested and been granted a trading halt on its ASX-listed securities, effective 19 March 2026, as it prepares to release clinical trial results derived from a central reading of new data. The halt, which is expected to re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.